← All trials
NCT04696328
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2019
- Primary completion
- May 30, 2022
- Completion date
- May 30, 2023
- First posted
- Jan 6, 2021
- Last posted
- Apr 20, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Osaka UniversityLead sponsor
- Osaka UniversityReponsible party - principal investigator
- Osaka UniversityStudy director
- Cuorips Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.